Literature DB >> 24526738

T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors.

Rikke Lyngaa1, Natasja Wulff Pedersen, David Schrama, Charlotte Albæk Thrue, Dafina Ibrani, Ozcan Met, Per Thor Straten, Paul Nghiem, Jürgen C Becker, Sine Reker Hadrup.   

Abstract

PURPOSE: Merkel cell carcinoma (MCC) is a highly aggressive skin cancer with strong evidence of viral carcinogenesis. The association of MCC with the Merkel cell polyomavirus (MCPyV) may explain the explicit immunogenicity of MCC. Indeed, MCPyV-encoded proteins are likely targets for cytotoxic immune responses to MCC as they are both foreign to the host and necessary to maintain the oncogenic phenotype. However, to date only a single MCPyV-derived CD8 T-cell epitope has been described, thus impeding specific monitoring of T-cell responses to MCC.
METHOD: To overcome this limitation, we scanned the MCPyV oncoprotein large T and small T antigens and the virus capsid protein VP1 for potential T-cell epitopes, and tested for MHC class I affinity. We confirmed the relevance of these epitopes using a high-throughput platform for T-cell enrichment and combinatorial encoding of MHC class I multimers.
RESULTS: In peripheral blood from 38 patients with MCC and 30 healthy donors, we identified 53 MCPyV-directed CD8 T-cell responses against 35 different peptide sequences. Strikingly, T-cell responses against oncoproteins were exclusively present in patients with MCC, but not in healthy donors. We further demonstrate both the processing and presentation of the oncoprotein-derived epitopes, as well as the lytic activity of oncoprotein-specific T cells toward MHC-matched MCC cells. Demonstrating the presence of oncoprotein-specific T cells among tumor-infiltrating lymphocytes further substantiated the relevance of the identified epitopes.
CONCLUSION: These T-cell epitopes represent ideal targets for antigen-specific immune therapy of MCC, and enable tracking and characterization of MCPyV-specific immune responses. ©2014 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24526738      PMCID: PMC3994405          DOI: 10.1158/1078-0432.CCR-13-2697

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  47 in total

1.  Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system.

Authors:  Bianca D Lemos; Barry E Storer; Jayasri G Iyer; Jerri Linn Phillips; Christopher K Bichakjian; L Christine Fang; Timothy M Johnson; Nanette J Liegeois-Kwon; Clark C Otley; Kelly G Paulson; Merrick I Ross; Siegrid S Yu; Nathalie C Zeitouni; David R Byrd; Vernon K Sondak; Jeffrey E Gershenwald; Arthur J Sober; Paul Nghiem
Journal:  J Am Acad Dermatol       Date:  2010-06-19       Impact factor: 11.527

2.  Generation of peptide-MHC class I complexes through UV-mediated ligand exchange.

Authors:  Boris Rodenko; Mireille Toebes; Sine Reker Hadrup; Wim J E van Esch; Annemieke M Molenaar; Ton N M Schumacher; Huib Ovaa
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

3.  Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7.

Authors:  Arnold H Bakker; Rieuwert Hoppes; Carsten Linnemann; Mireille Toebes; Boris Rodenko; Celia R Berkers; Sine Reker Hadrup; Wim J E van Esch; Mirjam H M Heemskerk; Huib Ovaa; Ton N M Schumacher
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

4.  Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.

Authors:  Laszlo G Radvanyi; Chantale Bernatchez; Minying Zhang; Patricia S Fox; Priscilla Miller; Jessica Chacon; Richard Wu; Gregory Lizee; Sandy Mahoney; Gladys Alvarado; Michelle Glass; Valen E Johnson; John D McMannis; Elizabeth Shpall; Victor Prieto; Nicholas Papadopoulos; Kevin Kim; Jade Homsi; Agop Bedikian; Wen-Jen Hwu; Sapna Patel; Merrick I Ross; Jeffrey E Lee; Jeffrey E Gershenwald; Anthony Lucci; Richard Royal; Janice N Cormier; Michael A Davies; Rahmatu Mansaray; Orenthial J Fulbright; Christopher Toth; Renjith Ramachandran; Seth Wardell; Audrey Gonzalez; Patrick Hwu
Journal:  Clin Cancer Res       Date:  2012-10-02       Impact factor: 12.531

5.  Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens.

Authors:  Roland Houben; Masahiro Shuda; Rita Weinkam; David Schrama; Huichen Feng; Yuan Chang; Patrick S Moore; Jürgen C Becker
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

6.  Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival.

Authors:  Kelly G Paulson; Jayasri G Iyer; Andrew R Tegeder; Renee Thibodeau; Janell Schelter; Shinichi Koba; David Schrama; William T Simonson; Bianca D Lemos; David R Byrd; David M Koelle; Denise A Galloway; J Helen Leonard; Margaret M Madeleine; Zsolt B Argenyi; Mary L Disis; Juergen C Becker; Michele A Cleary; Paul Nghiem
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

7.  High levels of antibodies against merkel cell polyomavirus identify a subset of patients with merkel cell carcinoma with better clinical outcome.

Authors:  Antoine Touzé; Emmanuelle Le Bidre; Hélène Laude; Maxime J J Fleury; Raphaël Cazal; Françoise Arnold; Agnès Carlotti; Eve Maubec; François Aubin; Marie-Françoise Avril; Flore Rozenberg; Mauro Tognon; Annabel Maruani; Serge Guyetant; Gérard Lorette; Pierre Coursaget
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

8.  Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features.

Authors:  Michelle Heath; Natalia Jaimes; Bianca Lemos; Arash Mostaghimi; Linda C Wang; Pablo F Peñas; Paul Nghiem
Journal:  J Am Acad Dermatol       Date:  2008-03       Impact factor: 11.527

9.  Quantitation of human seroresponsiveness to Merkel cell polyomavirus.

Authors:  Diana V Pastrana; Yanis L Tolstov; Jürgen C Becker; Patrick S Moore; Yuan Chang; Christopher B Buck
Journal:  PLoS Pathog       Date:  2009-09-11       Impact factor: 6.823

Review 10.  Merkel cell polyomavirus: a newly discovered human virus with oncogenic potential.

Authors:  Megan E Spurgeon; Paul F Lambert
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

View more
  37 in total

Review 1.  Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.

Authors:  Rocio Garcia-Carbonero; Ivan Marquez-Rodas; Luis de la Cruz-Merino; Javier Martinez-Trufero; Miguel Angel Cabrera; Jose Maria Piulats; Jaume Capdevila; Enrique Grande; Salvador Martin-Algarra; Alfonso Berrocal
Journal:  Oncologist       Date:  2019-04-08

Review 2.  Immunotherapy for Merkel Cell Carcinoma.

Authors:  Kotaro Nagase; Yutaka Narisawa
Journal:  Curr Treat Options Oncol       Date:  2018-09-20

3.  Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival.

Authors:  Natalie J Miller; Candice D Church; Lichun Dong; David Crispin; Matthew P Fitzgibbon; Kristina Lachance; Lichen Jing; Michi Shinohara; Ioannis Gavvovidis; Gerald Willimsky; Martin McIntosh; Thomas Blankenstein; David M Koelle; Paul Nghiem
Journal:  Cancer Immunol Res       Date:  2017-01-16       Impact factor: 11.151

Review 4.  Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma.

Authors:  Dirk Schadendorf; Paul Nghiem; Shailender Bhatia; Axel Hauschild; Philippe Saiag; Lisa Mahnke; Subramanian Hariharan; Howard L Kaufman
Journal:  Oncoimmunology       Date:  2017-08-31       Impact factor: 8.110

Review 5.  Large T and small T antigens of Merkel cell polyomavirus.

Authors:  Justin A Wendzicki; Patrick S Moore; Yuan Chang
Journal:  Curr Opin Virol       Date:  2015-02-11       Impact factor: 7.090

Review 6.  Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy.

Authors:  Teresa Amaral; Ulrike Leiter; Claus Garbe
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

Review 7.  Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC.

Authors:  Jürgen C Becker; Andreas Stang; Axel Zur Hausen; Nicole Fischer; James A DeCaprio; Richard W Tothill; Rikke Lyngaa; Ulla Kring Hansen; Cathrin Ritter; Paul Nghiem; Christopher K Bichakjian; Selma Ugurel; David Schrama
Journal:  Cancer Immunol Immunother       Date:  2017-11-30       Impact factor: 6.968

Review 8.  Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.

Authors:  Aric Colunga; Thomas Pulliam; Paul Nghiem
Journal:  Clin Cancer Res       Date:  2017-12-07       Impact factor: 12.531

Review 9.  Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.

Authors:  Daniela Femia; Natalie Prinzi; Andrea Anichini; Roberta Mortarini; Federico Nichetti; Francesca Corti; Martina Torchio; Giorgia Peverelli; Filippo Pagani; Andrea Maurichi; Ilaria Mattavelli; Massimo Milione; Nice Bedini; Ambra Corti; Maria Di Bartolomeo; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

10.  Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes.

Authors:  Amalie Kai Bentzen; Andrea Marion Marquard; Rikke Lyngaa; Sunil Kumar Saini; Sofie Ramskov; Marco Donia; Lina Such; Andrew J S Furness; Nicholas McGranahan; Rachel Rosenthal; Per Thor Straten; Zoltan Szallasi; Inge Marie Svane; Charles Swanton; Sergio A Quezada; Søren Nyboe Jakobsen; Aron Charles Eklund; Sine Reker Hadrup
Journal:  Nat Biotechnol       Date:  2016-08-29       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.